JPMorgan upgrades Nike to overweight, citing a multiyear recovery path

JPMorgan has upgraded Nike (NKE) shares to Overweight from Neutral, raising its price target to $93 from $64, signaling an approximate 18% upside from current levels. Analyst Matthew Boss anticipates a significant inflection point for Nike's model, projecting revenue growth re-acceleration into 2H26/FY27 as the company moves past inventory liquidation headwinds. The upgrade is predicated on Nike's opportunity to recapture over 500bps of operating margin erosion through improved full-price selling and new product innovation, with further long-term expansion expected to restore pre-pandemic profitability levels.

Analysis

JPMorgan has upgraded Nike (NKE) to Overweight from Neutral, increasing its price target to $93, which represents an approximate 18% upside from the stock's last closing price of $76.27. This upgrade is notable given the stock's flat performance year-to-date. The bank's thesis is predicated on a medium-term inflection point, with revenue growth expected to re-accelerate in the second half of fiscal 2026 and into fiscal 2027 as the company moves beyond inventory liquidation and product lifecycle headwinds. A key component of the bullish outlook is the potential for Nike to recapture over 500 basis points of operating margin erosion. This recovery is expected to be driven by improved full-price sell-through, positive reception to new product innovation, and operating leverage on SG&A expenses as top-line growth resumes. The analyst cites specific forward-looking catalysts, including the alignment of global inventory and sales by the end of Q2 2026 and 'very favorable' initial wholesale partner feedback on the Spring/Summer '26 product line. Over the longer term, beyond the firm's FY28 margin estimate of 10.0%, JPMorgan sees a path for an additional 200-300 basis points of margin expansion to return Nike to its historical pre-pandemic profitability levels of 12-13%.

Key Decisions for Investors

• Given the report's timeline for revenue re-acceleration in H2'26/FY'27, investors should approach NKE as a long-term holding, as the core thesis is a multi-year turnaround rather than a near-term catalyst.
• Investors should closely monitor key milestones cited in the analysis, particularly the progress toward global inventory and sales alignment by Q2 2026 and any management commentary on wholesale order book momentum.
• Considering the stock's recent underperformance, the current price could be viewed as an attractive entry point, but this is contingent on the company successfully executing on its product innovation pipeline, which has reportedly received favorable early feedback for Spring/Summer '26.